Company / Profit Margin
IOVANCE BIOTHERAPEUTICS, INC. Profit Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-148.4%
FY2025
5-year range
-37345.4% / -148.4%
FY2023-FY2025
Trend
+34.6%
vs FY2024
Sector context
#105 of 145
Health Care
What the data says
At -148.4%, IOVANCE BIOTHERAPEUTICS, INC.'s profit margin ranks #105 of 145 in the Health Care sector. Improved from -37345.4% to -148.4% over the past 2 years.
Based on SEC 10-K filings.
-148.4% in FY2025.
Improved from -37345.4% to -148.4% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#105 of 145 in Health CareTop 72% of 145This company -148.4% Sector average -792.7%
▼
+81.3% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 34.6% year-over-year.
- Currently 644.3pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -148.4% | +34.6% |
| FY2024 | -226.8% | +99.4% |
| FY2023 | -37345.4% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026